[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universitaire Ziekenhuizen KU Leuven\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":632},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,232,0,25,[9,39,72,99,121,146,178,203,224,245,270,297,324,353,378,397,422,446,466,488,518,540,559,584,612],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100053308","long-term-aseptic-revision--advanced-hip-arthroplasty-database-100053308",false,"NCT07481448","Long-term Aseptic Revision & Advanced Hip Arthroplasty Database","Long-term Follow-up of Patients Undergoing Aseptic Revision Hip Arthroplasty or Complex Primary Hip Arthroplasty Treated at University Hospitals Leuven","LARA","Inclusion Criteria:\n\n* Patients undergoing a hip replacement for the following indications:\n\n  1. THA with hardware removal\n  2. THA for hip dysplasia\n  3. THA with femoral deformity or prior corrective surgery\n  4. THA after LCPD, SCFE or septic arthritis\n  5. THA in metabolic disease\n  6. THA in hyperlaxity (e.g. Ehlers-Danlos syndrome, Down syndrome)\n  7. THA with complex bony anatomy\n  8. THA in patients aged 25 years or younger\n  9. Other indications for which the treating surgeon expects increased surgical difficulty or increased risk of postoperative complications\n\n     Exclusion Criteria:\n* Patients unable to provide written informed consent\n* Patients who prefer treatment outside of University Hospitals Leuven\n* Patients with proven PJI according to the 2021 EBJIS criteria\n* Patients undergoing standard, non-complex, hip replacement as judged by the treating physician.","ALL",{"count":20,"type":21},200,"ESTIMATED","OBSERVATIONAL","Total hip arthroplasty (THA) volumes continue to rise each year as the population ages and indications broaden. Increasingly, younger patients require hip replacement for conditions beyond primary osteoarthritis or fractures. As a result, the number of revision procedures is growing and is expected to increase further.\n\nProspective data collection within this population will enable us to address key uncertainties, particularly around optimal implant selection for complex primary and revision cases.\n\nIn addition, establishing a structured prospective database will allow for systematic internal auditing for quality assurance. Even simple metrics - such as verifying whether every patient received a complete diagnostic infection workup before revision surgery - could immediately enhance service quality and inform improvements to clinical pathways.",[25],"Hip Arthropathy Associated With Other Conditions","RECRUITING","2026-07-09",{"date":29,"type":30},"2026-07-13","ACTUAL",{"date":32,"type":21},"2026-07",{"date":34,"type":21},"2037-03",{"name":36,"class":37},"Universitaire Ziekenhuizen KU Leuven","OTHER",1,{"id":40,"slug":41,"hasResults":12,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":12,"sex":46,"minAge":47,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100645014","phase-2-clinical-study-of-local-and-systemic-biological-impact-of-glp1gip-receptor-agonists-in-patients-with-breast-cancer-the-clara-trial-100645014","NCT07676331","Clinical Study of Local and Systemic Biological Impact of GLP1\u002FGIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial","CLARA","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant has been obtained prior to any screening procedures\n2. Patient is \\>18 years of age\n3. Patient is postmenopausal, as defined per local practice\n4. Tumour size of ≥1 cm\n5. The patient has a biopsy-confirmed diagnosis of GII-III ER+, HER2 - early stage breast cancer scheduled for primary surgery as per standard-of-care\n\n   1. To fulfil the requirement for HR+ disease by local testing on primary disease specimen, tumour must be ER positive defined by immunohistochemistry (IHC) according to American Society of Clinical Oncology (ASCO)\u002FCollege of American Pathologists (CAP) guidelines for hormone receptor testing.\n   2. To fulfil the requirement of HER2- disease by local testing on primary disease specimen, tumour must be HER2- according to ASCO\u002FCAP guidelines for HER2 testing\n   3. All histological subtypes are eligible, including but not limited to invasive breast cancer of no special type (IBC-NST) , invasive lobular carcinoma (ILC) etc.\n6. Have a BMI of\n\n   1. ≥30 kg\u002Fm2 or\n   2. ≥27 kg\u002Fm2 and previously diagnosed with at least 1 of the following weight-related comorbidities:\n\n   i. Hypertension: treated or with systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg ii. Dyslipidaemia: treated or with LDL ≥160 mg\u002FdL (4.1 mmol\u002FL) or triglycerides ≥150 mg\u002FdL (1.7 mmol\u002FL), or HDL iii. Obstructive sleep apnoea iv. Cardiovascular disease, for example, ischemic cardiovascular disease, New York Heart Association Functional Classification Class I-III heart failure\n7. Patient should be able to read\u002Funderstand Dutch, French or English\n8. Willing to commit to the study program and comply with all related protocol procedures\n9. Willing to undergo a new biopsy of the breast lesion in case no formalin-fixed paraffin-embedded (FFPE) block can be made available for the trial.\n\nExclusion Criteria:\n\n1. Have Type 1 or 2 diabetes mellitus, history of ketoacidosis, or hyperosmolar state or coma.\n2. Have at least 1 laboratory value suggestive of diabetes during screening : HbA1c ≥6.5% (≥48 mmol\u002Fmol) or fasting glucose ≥126 mg\u002FdL (≥7.0 mmol\u002FL)\n3. Have a history of BC exceptions are made for:\n\n   1. Contralateral in situ BC without systemic treatment\n   2. Ipsilateral in situ BC without systemic treatment or radiation therapy\n4. Have a history of an additional invasive malignancy that is progressing or that has required active treatment in the 3 years prior to breast cancer diagnosis. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer\n5. Are receiving or has received within 3 months prior to screening systemic glucocorticoid therapy (excluding topical, intraocular, intranasal, intra-articular, or inhaled preparations) or have evidence of a significant, active autoimmune that has required (within the last 3 months) or is likely to require, in the opinion of the investigator, concurrent treatment with systemic treatment (such as glucocorticoids (excluding topical, intraocular, intranasal, intra-articular, or inhaled preparations)) during the course of the study.\n\n   Note: Replacement therapy with thyroxine is not a contraindication for inclusion if patient is already on same dose for 3 months\n6. Have a history of any other condition, such as known drug or alcohol abuse, diagnosed eating disorder, or other psychiatric disorder, that, in the opinion of the investigator, may preclude the participant from following and completing the protocol\n7. Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)\n8. Have a self-reported change in body weight \\>5 kg within 3 months prior to screening\n9. Have a prior surgical treatment for obesity, excluding liposuction or abdominoplasty\n10. Have endoscopic and\u002For device-based therapy for obesity or have had device removal within the last 6 months prior to screening\n11. Have renal impairment measured as eGFR \\\u003C30L\u002Fmin\u002F1.73m2\n12. Have a known clinically significant gastric emptying abnormality (for example, severe gastroparesis or gastric outlet obstruction) or chronically take drugs that directly affect GI motility\n13. Have a history of chronic or acute pancreatitis\n14. Is treated with insulin or other hypoglycaemic drugs\n15. Participation in another interventional Trial with an investigational medicinal product (IMP) or device in the neoadjuvant setting\n16. Have obesity induced by other endocrinologic disorders, for example, Cushing syndrome, or diagnosed monogenetic or syndromic forms of obesity\n17. Has acute or chronic hepatitis, signs and symptoms of any other liver disease other than NAFLD, or any of the following, as determined by the central laboratory during screening:\n\n    1. Alanine aminotransferase (ALT) level \\>3.0x ULN for the reference range\n    2. Alkaline phosphatase (ALP) level \\>2.0x ULN for the reference range, or\n    3. Total bilirubin level \\>1.5x ULN for the reference range (except for cases of known Gilbert's Syndrome) Note: Participants with non-alcoholic fatty liver disease (NAFLD) are eligible to participate in this trial if their ALT level is ≤3.0x ULN for the reference range\n18. Has used systemic hormonal substitution therapy within 2 months before screening\n19. Has used a GLP1\u002F(GIP)\u002F(GC) Receptor Agonist within 2 months of screening\n20. Has used medications (prescribed or over-the-counter) within 2 months prior to screening that promote weight loss.","FEMALE","18 Years",{"count":49,"type":21},168,"INTERVENTIONAL",[52],"PHASE2","The CLARA trial is a phase II window-of-opportunity trial evaluating how a commonly used weight-loss medication (tirzepatide, a GLP-1\u002FGIP receptor agonist) affects breast cancer biology, alone and in combination with standard hormone therapy (letrozole).\n\nThe main goal is to determine whether tirzepatide, alone or combined with letrozole, reduces tumor cell growth.",[55,56],"Hormone-receptor-positive Breast Cancer","Early Breast Cancer",[58,59,60,61,62],"GLP-1\u002FGIP receptor agonist","tirzepatide","letrozole","Window-of-opportunity trial","Weight-loss drugs","NOT_YET_RECRUITING","2026-06-23",{"date":66,"type":30},"2026-06-30",{"date":68,"type":21},"2026-08-01",{"date":70,"type":21},"2028-05-01",{"name":36,"class":37},{"id":73,"slug":74,"hasResults":12,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":12,"sex":46,"minAge":47,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":50,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},"100613749","lifestyle-intervention-to-improve-twin-pregnancy-outcomes-100613749","NCT07270640","Lifestyle Intervention to Improve Twin Pregnancy Outcomes","Lifestyle Intervention to Improve Twin Pregnancy Outcomes: an Integrated Pilot Study for a Multicentric Randomized Controlled Trial","LIFETWIN","Inclusion Criteria:\n\n* Prior to any randomization or intervention, participants must have provided voluntary written informed consent.\n* Diagnosis of dichorionic twin pregnancies must align with the acceptance criteria.\n* Participants must be recruited before the 14th week of gestation.\n* Proficiency in Dutch, English, or French is required.-\n\nExclusion Criteria:\n\n* Participant has a history of pre-existing diseases or condition impacting their diet:\n\n  1. pre-gestational diabetes\n  2. severe heart disease,\n  3. chronic renal disease,\n  4. celiac disease,\n  5. inflammatory bowel disease,\n  6. post-bariatric surgery\n* Participant has a history of pre-existing diseases or conditions impacting their physical activity ability:\n\n  1. Chronic Obstructive Pulmonary Disease (COPD)\n  2. Severe Asthma.\n  3. Fibromyalgia\n  4. Osteoarthritis\n  5. Chronic Pain Syndromes\n  6. Spinal Cord Injuries.\n  7. Multiple Sclerosis (MS)\n  8. Parkinson's Disease\n  9. History of a Stroke\n  10. Drug resistance Epilepsy\n* Participants identified with mental vulnerabilities requiring specific care pathways by Born in Belgium (BIB) or local screening tool.\n* Participants with a History of Mental Health Disorders\n\n  1. Post-Traumatic Stress Disorder (PTSD)\n  2. Anxiety Disorders\n  3. Depressive Disorders\n  4. Bipolar Disorder\n  5. Obsessive-Compulsive Disorder (OCD)\n  6. Schizophrenia or schizoaffective disorder\n* Inability to give informed consent\n* No knowledge of Dutch, English or French\n* First trimester diagnosis of severe congenital anomaly in one or both twins\n* First trimester foetal demise of one or both twins\n* Rupture of membranes prior to recruitment\n* Participation in any other interventional Study",{"count":81,"type":21},81,[83],"NA","The goal of this clinical trial to is assess the benefits of holistic lifestyle interventions, including nutrition, physical activities, and mindfulness, aiming to reduce preterm birth in twins, potentially revolutionizing twin care globally.\n\nAn initial integrated pilot study is be conducted to assess and refine the intervention methods. The primary objective of the pilot study is to evaluate feasibility. If deemed feasible, the full study will be implemented, incorporating data from pilot study participants into the main study.\n\nObjective of the full study: To evaluate if a multi-component lifestyle extends gestational age at delivery by one week. Additional objective: to evaluate if the intervention positively influences multiple secondary outcomes including pregnancy complications, neonatal and maternal outcomes, and maternal quality of life.",[86],"Twin Pregnancy, Dichorionic",[88,89,90],"twin pregnancy","dichorionic","lifestyle interventions",{"date":92,"type":30},"2026-06-26",{"date":94,"type":30},"2025-12-05",{"date":96,"type":21},"2027-06",{"name":36,"class":37},4,{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":4},"100644786","improving-prognostication-in-colon-cancer-100644786","NCT07673393","Improving Prognostication in Colon Cancer","Improving Prognostication of Localised Colon Cancer by Combining Liquid Biopsy and Histology: a Multicentric, Prospective Study","MARBLE","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n2. Male and female participants, at least 18 years of age at the time of signing the Informed Consent Form (ICF).\n3. Newly diagnosed primary colon tumor clinically and\u002For histologically consistent with localized colon adenocarcinoma and planned for curative-intent surgical resection.\n4. Clinical stage compatible with non-metastatic disease at time of screening and considered eligible for standard curative-intent management according to investigator assessment.\n5. WHO (ECOG) performance status ≤ 3 at baseline.\n\nExclusion Criteria:\n\n1. Participant has been diagnosed with metastatic disease (Stage IV)\n2. Participant has been diagnosed with rectal cancer\n3. Participant has been diagnosed with synchronous primary colon tumors (i.e., presence of two or more primary colon tumors detected simultaneously at diagnosis)\n4. Participant has received prior systemic therapy (chemotherapy, targeted therapy, immunotherapy, or radiotherapy) for colon cancer\n5. Participation in an interventional Study with an investigational medicinal product (IMP) or device within 30 days prior to inclusion.\n6. Participant had prior history of colon cancer requiring systemic treatment or major colorectal oncologic surgery.\n7. Any severe, uncontrolled, or life-threatening medical condition that, in the opinion of the investigator, could interfere with study participation, interpretation of study assessments, or pose excessive risk to the participant (e.g. severe cardiac, hepatic, renal, or uncontrolled infectious disease).",{"count":108,"type":21},400,"The goal of this study is to test better ways to predict if cancer will return after surgery in adults (18+) who have been diagnosed with stage II or III colon cancer.\n\nThe main questions it aims to answer are:\n\n* Can computer programs (Artificial Intelligence) and special blood tests give more accurate information about the risk of cancer returning than the methods doctors use today?\n* Does combining these new tests help doctors better understand which patients really need chemotherapy and which do not?\n\nResearchers will compare the new computer and blood tests to the standard hospital methods used now to see if the new way is more accurate in predicting the cancer's behavior\n\nParticipants will:\n\n* Sign a form saying they agree to take part in the study\n* Have their standard surgery to remove the tumor\n* Give a few extra teaspoons of blood during their regular, scheduled hospital visits\n* Allow researchers to scan and study a small piece of the tumor that was already removed during surgery\n* Continue with their normal hospital check-ups for up to five years so researchers can track their health",[111,112],"Colon Cancer","Colon Adenocarcinoma","2026-06-22",{"date":115,"type":30},"2026-06-29",{"date":117,"type":21},"2026-09",{"date":119,"type":21},"2033-09",{"name":36,"class":37},{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":129,"sex":18,"minAge":130,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":50,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":38},"100644106","blood-based-biomarkers-for-alzheimers-disease-at-the-primary-care-level-100644106","NCT07666113","Blood-based Biomarkers for Alzheimer's Disease at the Primary Care Level.","The Diagnostic Validity and Clinical Impact of Blood-based Biomarkers for the Diagnosis of Alzheimer's Disease at the Primary Care Level.","ADPriK","Inclusion Criteria:\n\n* Patients between 55 and 85 years old who consult their PCP due to concerns about their cognitive status.\n\nExclusion Criteria:\n\n* Comorbidities that would interfere with study cooperation or interpretability of study results (for instance substance abuse or cardiac, renal or hepatic failure).\n* Concomitant medications that would interfere with cognitive assessments.\n* A prior diagnosis of AD and related disorders or other neurodegenerative disease.",true,"55 Years","85 Years",{"count":133,"type":21},240,[83],"The goal of this study is to determine how blood biomarker tests (ptau217 and ptau217\u002FAβ42) performed in primary care influence the patient trajectory in individuals with cognitive concerns.\n\nParticipants will provide a blood sample for biomarker testing and undergo clinical assessments as part of diagnostic evaluation.",[137],"Alzheimer's Disease (AD)","2026-06-17",{"date":140,"type":30},"2026-06-24",{"date":142,"type":30},"2026-05-26",{"date":144,"type":21},"2038-04",{"name":36,"class":37},{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":152,"eligibilityCriteria":153,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":50,"phases":156,"briefSummary":157,"conditions":158,"keywords":164,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":38},"100633236","the-application-of-infrared-thermography-in-the-prediction-of-skin-healing-in-surgery-100633236","NCT07524062","The Application of Infrared Thermography in the Prediction of Skin Healing in Surgery","The Application of Infrared Thermography in the Prediction of Skin Healing in Surgery THERMS: THermography for Evaluation of Recovery and Monitoring of Surgical Wounds","THERMS","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n2. Adult subjects (\\>18 years of age) at time of enrolment\n3. Patients undergoing a surgical excision under local anesthesia\n4. Indications of the excisions were skin lesions suspected to be malignant, skin lesions confirmed to be malignant via prior biopsy\n\nExclusion Criteria:\n\n1. Patient has history of pre-existing diabetes type I and II\n2. Patients with pre-existing chronic wound problems\n3. Patients with renal dysfunction,\n4. Patients with venous insufficiency confirmed via radiographic imaging\n5. Patients who received radiotherapy in the affected area in the past\n6. Patients with chronic steroid use in the past (\\> 3 months) or a immunosuppressant medication history\n7. Female who is pregnant",{"count":155,"type":21},120,[83],"This study investigates whether infrared thermography, a harmless and non-invasive thermal camera technique, can help monitor how surgical wounds heal after skin surgery. The goal is to detect wound problems earlier, such as infection or delayed healing, and to support doctors in making timely clinical decisions.",[159,160,161,162,163],"Wound Healing","Surgical Wound Infection","Postoperative Complications","Skin Neoplasms","Skin Transplantation",[165,166,167,168,169],"Infrared thermography","Surgical wound healing","Dermatosurgery","Thermal imaging","Wound complications","2026-06-16",{"date":172,"type":30},"2026-06-18",{"date":174,"type":30},"2026-06-15",{"date":176,"type":21},"2028-10",{"name":36,"class":37},{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":187,"conditions":188,"keywords":191,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":38},"100613404","prospective-collection-of-clinical-data-and-human-body-material-hbm-of-cutaneous-melanoma-non-melanoma-patients-and-healthy-controls-biobank-huidkanker-100613404","NCT07266142","Prospective Collection of Clinical Data and Human Body Material (HBM) of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker","Prospective Collection of Clinical Data and Human Body Material (HBM): Blood (Serum, Plasma, DNA) and Tissue of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n* Adult subjects (\\>18 years of age) at time of enrolment.\n* Subjects diagnosed with cutaneous melanoma, Non-melanoma skin cancer or healthy controls.\n* Adult subjects able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Subjects unable or not willing to provide informed consent.\n* Pregnancy (or willing to become pregnant) is NOT an exclusion criteria (unless specified in the respective satellite protocols.",{"count":186,"type":21},7500,"The goal of this clinical trial is to set up a prospective, fit-for-purpose collection of human body material (HBM)-blood (serum, plasma, DNA) and tissue-and standardized clinical data of patients with cutaneous melanoma, non-melanoma skin cancer and healthy controls.\n\nThe main questions it aims to answer are:\n\n* To create a biobank with samples of human body material (HBM): blood (serum\u002Fplasma\u002FDNA) and tissue and clinical data of patients with cutaneous melanoma, non-melanoma and helathy controls.\n* To support future research questions (after specific approval of the Ethics Committee) by using the biobank (through satellite protocols).\n\nIf there is a comparison group: Not applicable (umbrella protocol for collection only).\n\nParticipants will:\n\n* Share demographics, medical and surgical history, risk factors.\n* Complete Cancer Worry Scale questionnaire.\n* Provide biological samples:\n\n  * Blood samples (serum, plasma, DNA).\n  * Tissue samples (residual tissue or additional biopsy if consented).",[189,190],"Skin Cancer, Non-Melanoma","Skin Cancer Melanoma",[192,193,194],"Prospective Collection","Skin Cancer","Human Body Material","2026-06-10",{"date":197,"type":30},"2026-06-12",{"date":199,"type":30},"2025-11-17",{"date":201,"type":21},"2051-01",{"name":36,"class":37},{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":210,"targetDuration":212,"studyType":22,"phases":4,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":38},"100643071","validation-of-sds-edta-treated-chromatography-paper-strips-for-mpox-sampling-and-transport-in-drc-100643071","NCT07634081","Validation of SDS-EDTA-Treated Chromatography Paper Strips for Mpox Sampling and Transport in DRC","Use of SDS\u002FEDTA-Treated Chromatography Strips for Sampling, Transportation and Laboratory Confirmation of Mpox Virus Infection","Inclusion Criteria:\n\n* Patients presenting with clinical signs compatible with mpox infection according to national case definition.\n* Written informed consent obtained.\n* Presence of at least two skin lesions in a similar stage of evolution suitable for paired sampling.\n\nExclusion Criteria:\n\n* Refusal or inability to provide informed consent.\n* Presence of only one suitable lesion for sampling.\n* Lesions at markedly different stages of evolution.\n* Inability to safely obtain paired samples.",{"count":211,"type":21},150,"1 Day","The objective of this prospective paired diagnostic comparison study is to evaluate the diagnostic yield and field applicability of SDS-EDTA-treated chromatography paper strips for the collection, transport, and laboratory detection of mpox virus compared with the routine swab-based sampling method under field conditions in the Democratic Republic of the Congo (DRC).\n\nThe study is conducted among patients with suspected mpox infection presenting to healthcare facilities in South Kivu, DRC. For each participant, paired samples are collected simultaneously using the standard swab method and the SDS-EDTA strip method. Samples are analyzed using locally available molecular diagnostic platforms.",[215],"Mpox","2026-06-09",{"date":218,"type":30},"2026-06-11",{"date":220,"type":30},"2026-05-01",{"date":222,"type":21},"2026-07-31",{"name":36,"class":37},{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":231,"targetDuration":233,"studyType":22,"phases":4,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":38},"100643504","cardiac-surgery-the-incidence-and-impact-of-chronic-postoperative-pain-a-survey-100643504","NCT07640646","Cardiac Surgery, the Incidence and Impact of Chronic postOperative Pain: a Survey","Cardiac COPS","Inclusion Criteria:\n\n1. Adults, aged ≥ 18 years of age, who underwent cardiac surgery (valvular, coronary bypass, other intracardiac or aortic surgery) during the 1 year recruitment period\n2. Able to provide informed consent\n3. Able to respond by telephone\n\nExclusion Criteria:\n\n1. Deceased\n2. Refusal\n3. Chronic pain in the surgical region",{"count":232,"type":21},1000,"1 Year","This survey study aims to investigate the incidence of Chronic post surgical pain (CPSP) in cardiac surgery patients treated at UZ Leuven. The primary hypothesis is that the incidence of CPSP at 3 months postoperatively is lower than 33%, which is the rate commonly reported in the literature. Secondary objectives include comparing CPSP incidence based on the type of surgical incision, as well as comparing incidences between type of surgery. Finally, the study will assess pain intensity, interference with daily activities, and quality of life of 3 months and when required also at 1 years postoperatively.",[236,237],"Chronic Postoperative Pain","Cardiac Surgery","2026-06-05",{"date":218,"type":30},{"date":241,"type":30},"2026-06-01",{"date":243,"type":21},"2028-05-31",{"name":36,"class":37},{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":46,"minAge":47,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":50,"phases":255,"briefSummary":256,"conditions":257,"keywords":259,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":263,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":269},"100539939","continuous-glucose-monitoring-for-women-with-gestational-diabetes-100539939","NCT06310356","Continuous Glucose Monitoring for Women With Gestational Diabetes","Continuous Glucose Monitoring for Women With Gestational Diabetes: a Randomized Controlled Trial","CORDELIA","Inclusion Criteria:\n\n* At least 18 years of age at the time of signing the Informed Consent Form (ICF)\n* Singleton pregnancy\n* Diagnosed with gestational diabetes before 29.6 weeks of pregnancy\n* Needs to be able to understand and speak Dutch, French or English.\n* Have email access\n\nExclusion Criteria:\n\n* Patient has a history of type 2 or type 1 diabetes, or presence of auto-immune antibodies for type 1 diabetes\n* A physical or psychological disease likely to interfere with the conduct of the study (based on the evaluation by the treating physician).\n* Use of medication with significant impact on glycemia (such as high dose glucocorticoids and diabetes medication such as metformin)\n* Participation in an interventional Trial with an investigational medicinal product or device\n* Multiple pregnancy\n* History of bariatric surgery\n* Known allergy to the adhesives used with the continuous glucose monitoring",{"count":254,"type":21},386,[83],"There are a few ongoing large randomized controlled trials (RCT's) on continuous glucose monitoring (CGM) in women with gestational diabetes (GDM) powered for pregnancy outcomes. However, none of these studies included women diagnosed with early GDM. The CORDELIA trial is a Belgian-Australian open-label multi-centric RCT with 16 centers in women with GDM (including both early and late GDM). Women will be randomized 1\u002F1 to either treatment with CGM (intervention group, Freestyle Libre 3 +) or continue with self-monitoring of blood glucose (SMBG) with glucometer in line with normal routine (control arm). The study ends at the postpartum oral glucose tolerance test (OGTT 6-24 weeks postpartum) to screen for glucose intolerance.",[258],"Gestational Diabetes",[260,261,262],"gestational diabetes","continuous glucose monitoring","early gestational diabetes",{"date":216,"type":30},{"date":265,"type":30},"2024-11-18",{"date":267,"type":21},"2027-08",{"name":36,"class":37},16,{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":276,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":50,"phases":280,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":296},"100613741","accelerated-pacing-and-cardiac-filling-pressures-during-exercise-in-patients-with-heart-failure-with-preserved-ejection-fraction-100613741","NCT07270536","Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection Fraction","The Impact of Accelerated Pacing and AV-delay Regulation on the Pulmonary Capillary Wedge Pressure During Exercise in Patients With HFpEF","APAVE","Participants eligible for inclusion in this study must meet all of the following criteria:\n\n1. Voluntary written informed consent of the participant has been obtained prior to any screening procedures\n2. At least 18 years of age at the time of signing the Informed Consent Form (ICF)\n3. Heart failure with preserved ejection fraction, defined as one of the below criteria:\n\n   1. EF \\>= 45% and HFA-PEFF score \\>= 5 (Heart Failure Association-Pre-test assessment, Echocardiography and natriuretic peptide, Functional testing, Final etiology; heart failure association of the European Society of Cardiology and the Heart Failure Association (34))\n   2. EF \\>= 45% and H2FPEF score \\>= 6 (Heavy, Hypertensive, Atrial fibrillation, Pulmonary hypertension, Elder, Filling pressure; Mayo Clinic group (35)))\n   3. EF \\>= 45% and\n\n   i. History of heart failure hospitalization after pacemaker implantation or ii.On loop-diuretics at time of inclusion\n4. Having a DDD-pacemaker with LBB area pacing, implanted at least 12 weeks before iCPET\n5. \\>=6 weeks on optimal HFpEF therapy (MRA and SGLT2i) at time of iCPET, unless contraindicated or not tolerated\n6. Sinus rhythm at time of screening and iCPET\n\nParticipants eligible for this Study must not meet any of the following criteria:\n\n1. Participant has a history of:\n\n   1. Evidence of significant pulmonary comorbidity based on abnormal pulmonary function tests (FEV1 \\\u003C60%) or aberrant lung parenchyma more than mild on radiological imaging\n   2. Severe\u002Fsymptomatic valvular diseases\n   3. Severe pulmonary hypertension (PASP \\> 55mmHg estimated by Doppler Echo)\n   4. Unstable arrhythmias (VT, VF)\n   5. Recurrent syncopes after pacemaker implantation\n   6. Permanent atrial fibrillation\n   7. Amyloid cardiomyopathy\n2. Physical inability to perform exercise\n3. More than 1 hospitalization for heart failure in the last year\n4. Resting heart rate\\> 100bpm\n5. At time of iCPET or inclusion: decompensated heart failure, unstable coronary syndrome\n6. Contraindication to central venous access\n\n   1. Severe coagulopathy (e.g., spontaneous INR \\> 2, thrombocytopenia \\\u003C 50,000\u002FµL)\n   2. Local infection or skin infection at the insertion site\n   3. Thrombosis or anatomical abnormalities of the right jugular vein\n   4. Pneumothorax or contralateral lung pathology\n   5. Inability to properly position the patient\n7. Contraindication to arterial access\n\n   1. Thrombosis or occlusion of the target artery\n   2. Raynaud's phenomenon or other vasospastic disorders\n   3. Active infection at the intended insertion site\n   4. Severe coagulopathy (e.g., spontaneous INR \\> 2, thrombocytopenia \\\u003C 50,000\u002FµL)\n   5. Insufficient collateral circulation (e.g., inadequate perfusion in an Allen test)\n8. Contraindications to CPET\n\n   1. ECG signifying myocardial injury\n   2. ECG signifying current or potentially lethal arrhythmias\n   3. Systemic hypotension (e.g. systolic blood pressure \\\u003C 90 mmHg)\n   4. Extreme hypertension (e.g. systolic blood pressure \\> 220 mmHg)\n   5. Syncope, presyncope, or lightheadedness\n   6. SaO2 \\\u003C 88%\n   7. Severely elevated PCWP (\\> 40 mmHg) during exercise",{"count":279,"type":21},20,[83],"What is HFpEF? In heart failure with preserved ejection fraction (HFpEF), the heart pumps well but struggles to relax and fill with blood between beats. This raises the pressure inside the heart, especially during physical activity, causing symptoms like shortness of breath and fatigue - even with light activities like walking or climbing stairs.\n\nWhat is this study about? Recent research suggests that a higher heart rate may help lower this elevated pressure. Many HFpEF patients already have a pacemaker. This study investigates whether simply increasing the pacemaker rate during light exercise can reduce the pressure in the heart.\n\nHow does the study work? We wille measure heart pressures in 20 patients in rest and while cycling using a heart catheter and monitor their breathing. Throughout these measurements, we will gradually increase the pacemaker rate step by step.\n\nWhy does this matter? If a higher pacemaker rate successfully lowers heart pressure, this could offer a simple, drug-free way to improve daily functioning and comfort for thousands of patients with HFpEF, justifying further long-term studies to evaluate effects beyond the immediate changes in heart pressures.",[283],"HFpEF",[285,286,287,288],"Heart Failure with Preserved Ejection Fraction","Accelerated pacing","Chronotropic response","Hemodynamics","2026-06-02",{"date":238,"type":30},{"date":292,"type":30},"2025-12-10",{"date":294,"type":21},"2027-03-01",{"name":36,"class":37},2,{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":304,"enrollmentInfo":305,"targetDuration":4,"studyType":50,"phases":307,"briefSummary":308,"conditions":309,"keywords":311,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":38},"100555523","eus-guided-response-assessment-to-nsbb-100555523","NCT06513195","EUS-guided Response Assessment to NSBB","Endoscopic Ultrasound Guided Response Assessment to Non-selective Beta-blockers in the Treatment of Clinically Significant Portal Hypertension","Inclusion Criteria:\n\n* Patients with a clinical and\u002For pathological diagnosis of compensated cirrhosis.\n* Patients with suspicion of CSPH and thus indication for NSBB treatment.\n* Patients not yet on NSBB therapy.\n* Patients willing and able to undergo repeated HVPG and EUS-guided pressure measurements as per protocol.\n\nExclusion Criteria:\n\nGeneral criteria\n\n* Patient is \\\u003C18 or \\>80 years of age\n* Patient is pregnant, breast-feeding or planning to become pregnant during the course of the study\n* Patient is unwilling or unable to sign the informed consent\n* Patients in whom general anesthesia or endoscopic procedures are contraindicated Medical criteria\n* Patients with cirrhosis and HCC Portopulmonary hypertension Portal or splanchnic venous thrombosis Prior TIPS Prior liver transplantation\n* Non-cirrhotic portal hypertension or pre-sinusoidal liver disease\n* Cholestatic liver disease with total bilirubin \\>3 mg\u002Fdl\n* Previous total or partial splenectomy\n* Known infection that is not controlled by medical intervention\n* Patients with contraindications for non-selective beta-blocker therapy, including but not limited to the following baseline vital signs:\n\nSystolic BP \\\u003C100 mmHg HR \\\u003C50 bpm\n\n* Patients with reduced life expectancy described by an ASA score of 4 or 5\n* INR \\>1.7 or platelet count \\\u003C50.000 per mm3\n* eGFR \\\u003C50 ml\u002Fmin\u002F1.73m2 (CKD-EPI formula) Anatomical criteria\n* Anatomical abnormalities that prevent access via EUS-guided puncture to the hepatic vein or intrahepatic portion of the portal vein, including anatomy that predisposes to difficult to reach puncture sites or an inadequate needle angle.\n* Visualization of ascites interposing the puncture tract on EUS\n* Diagnosis of portal vein thrombosis during EUS\n* Evidence of active gastrointestinal bleeding during EUS","80 Years",{"count":306,"type":21},24,[83],"The goal of this clinical trial is to learn if endoscopic ultrasound (EUS)-guided portal pressure measurement can determine the treatment response to non-selective beta-blockers (NSBB) in patients with cirrhosis and clinically significant portal hypertension (CSPH). Participants will undergo EUS-guided portal pressure measurement before start of Carvedilol en after three months of treatment. EUS-guided measurements will be paired with transjugular hepatic venous pressure gradient (HVPG) measurement as well as non-invasive tests for assessment of portal hypertension.",[310],"Portal Hypertension Related to Cirrhosis",[312,313,314,315,316],"portal hypertension","EUS-PPG","HVPG","cirrhosis","non-selective beta blockers",{"date":318,"type":30},"2026-06-03",{"date":320,"type":30},"2024-07-17",{"date":322,"type":21},"2026-12",{"name":36,"class":37},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":12,"sex":46,"minAge":47,"maxAge":4,"enrollmentInfo":332,"targetDuration":4,"studyType":50,"phases":334,"briefSummary":336,"conditions":337,"keywords":339,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":345,"lastUpdatePostDateStruct":346,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":352},"100483033","phase-3-semaglutide-for-the-treatment-of-glucose-intolerance-in-women-with-prior-gestational-diabetes-100483033","NCT05569772","Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes","Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes: a Double Blind RCT","SERENA","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant has been obtained prior to any screening procedures\n2. Women aged ≥18 years\n3. Use of highly effective methods of birth control\n4. History of GDM diagnosed according to the 2013 WHO criteria (at 24-32 weeks gestation or \\\u003C24 weeks for early GDM)\n5. Diagnosis of prediabetes between 6 weeks and 12 months postpartum according to ADA criteria (FPG 5.6-6.9 mmol\u002FL, 2-hour OGTT glucose 7.8-11.0 mmol\u002FL and\u002For HbA1c 39-46 mmol\u002Fmol \\[5.7-6.4%\\])\n\nExclusion Criteria:\n\n1. Presence of autoantibodies suggestive of type 1 diabetes, normal glucose tolerance, history of pancreatitis, previous bariatric surgery or planned surgery within two years\n2. Unable to understand and speak Dutch, French or English\n3. Female who is pregnant or intends to become pregnant within the next year\n4. Female who wants to give breastfeeding \\>22 months\n5. Use of medication with significant impact on glycaemia (such as high dose glucocorticoids or metformin)",{"count":333,"type":21},252,[335],"PHASE3","Gestational diabetes (GDM) is an important contributor to the increasing prevalence of type 2 diabetes (T2DM). Women with glucose intolerance in early postpartum are a particularly high-risk group with about 50% who will develop T2DM within 5 years after the delivery. Moreover, women with a history of GDM progress more rapidly to T2DM compared to women with similarly elevated glucose levels. Early intervention after the index pregnancy is therefore crucial to prevent T2DM. With the SERENA project, the investigators aim to reduce the risk to develop T2DM with the long-acting GLP-1 agonist semaglutide in women with a recent history of GDM and glucose intolerance in early postpartum.",[338],"Glucose Intolerance After a Recent History of Gestational Diabetes",[260,340,341,342,343,344],"glucose intolerance postpartum","prevention","type 2 diabetes","GLP-1 agonist","semaglutide","2026-05-28",{"date":289,"type":30},{"date":348,"type":30},"2023-09-14",{"date":350,"type":21},"2029-12",{"name":36,"class":37},13,{"id":354,"slug":355,"hasResults":12,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":359,"eligibilityCriteria":360,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":361,"targetDuration":4,"studyType":50,"phases":363,"briefSummary":364,"conditions":365,"keywords":367,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":98},"100639637","improving-the-use-of-immunotherapy-to-treat-liver-cancer-100639637","NCT07623265","Improving the Use of Immunotherapy to Treat Liver Cancer","Optimizing and Improving Immunotherapy for Hepatocellular Carcinoma: the IO-MARC Study","IO-MARC","* General inclusion Criteria:\n\n  1. Male or female, age \\> 18 years\n  2. Diagnosis or suspected diagnosis of hepatocellular carcinoma based on imaging\n* Specific inclusion criteria cohort 1 (retrospective\u002Fprospective data may be applicable):\n\n  1. Pathologically confirmed HCC\n  2. Treated with systemic treatment \\[tyrosine kinase inhibitor (TKI) or immunotherapy (ICI)\\] in the last 7 years and follow-up data (at least one imaging on treatment) available until 01\u002F01\u002F2025\n  3. Biopsy obtained between 01\u002F01\u002F2018 until 01\u002F01\u002F2025\n  4. Left-over tissue from previous diagnostic biopsies or resection specimens available\n  5. Time between biopsy and initiation of systemic treatment \\\u003C 1 year\n  6. Ability to sign informed consent for secondary use of archival tissue and data collection for study-specific research for patients who are alive\n* Specific inclusion criteria cohort 2 (aHCC \\& prospective):\n\n  1. Suspicion of hepatocellular carcinoma (imaging criteria or recurrent disease of previously treated HCC)\n  2. Indication for tumor biopsy per standard of care\n  3. Eligible for systemic treatment (any) after pathological confirmation of HCC\n  4. Ability to sign informed consent for primary use of tissue and blood samples and data collection for study-specific research\n* Specific inclusion criteria cohort 3 (eHCC \\& prospective):\n\n  1. Suspicion of hepatocellular carcinoma (imaging criteria or recurrent disease of previously treated HCC)\n  2. Indication for local treatment (resection or ablation)\n  3. Ability to sign informed consent for primary use of tissue and blood samples and for data collection for study-specific research\n\n     Due to the observational nature of this study, participation in other (interventional) clinical trials is permitted, if biological materials can be collected per protocol.\n* General exclusion criteria:\n\n  1. Poor liver function and\u002For performance status which prohibits active treatment\n  2. Pathologically proven other malignancies of the liver, including primary cholangiocarcinoma or liver metastases\n  3. Treatment plan other than systemic treatment or local treatment (resection or ablation), such as TACE, TARE, liver transplantation",{"count":362,"type":21},300,[83],"This project targets patients with a form of primary liver cancer, specifically \"hepatocellular carcinoma\". This disease often develops in the context of a chronically diseased liver, caused by viral infections, excessive alcohol consumption, or fatty liver. Primarily due to the rise of the latter risk factor, liver cancer is one of the few cancer types whose incidence continues to increase globally, year after year. As a result, liver cancer has become the third most common cause of cancer-related deaths worldwide. There exists a significant challenge in reducing the disease on all fronts: prevention, diagnosis, and treatment.\n\nThis research aims to personalize the treatment of liver cancer patients, tailoring it to the individual. More specifically, this research seeks to identify patients with immunotherapy-sensitive liver cancer by biomarkers before treatment begins. Determining whether a tumor is immunotherapy-sensitive is internationally recognized as one of the most important challenges within this condition. Based on a combination of existing laboratory techniques on tumor tissue and\u002For blood, the investigators seek to predict the likelihood of this treatment's success before initiating it. With this knowledge, the investigators could recommend alternative treatments to patients with tumors that are unresponsive. This way, they would also avoid exposure to the side effects of an ineffective therapy.",[366],"Hepatocellular Carcinoma (HCC)",[368,369,370],"Biomarker","Hepatocellular carcinoma","Immunotherapy","2026-05-27",{"date":318,"type":30},{"date":374,"type":30},"2025-03-04",{"date":376,"type":21},"2032-01",{"name":36,"class":37},{"id":379,"slug":380,"hasResults":12,"nctId":381,"briefTitle":382,"officialTitle":383,"acronym":4,"eligibilityCriteria":384,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":385,"targetDuration":4,"studyType":50,"phases":387,"briefSummary":388,"conditions":389,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":391,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":98},"100493390","liquid-biopsies-in-esophageal-cancer-100493390","NCT05704530","Liquid Biopsies in Esophageal Cancer","Personalized Multimodal Treatment for Resectable Esophageal Cancer by Detecting Minimal Residual Disease Using Circulating Tumor DNA: a Multicentric Prospective Study","Key inclusion criteria are:\n\n1. Male or female, age \\> 18 years\n2. New diagnosis of esophageal cancer, pathologically confirmed squamous cell carcinoma (ESCC) or adenocarcinoma (EAC)\n3. Clinically staged - cT1-4 N0-2 M0 (local or locally advanced, resectable)\n4. Eligible for multidisciplinary treatment as assessed by MDT\n5. Able to provide informed consent (ICF) according to Good Clinical Practice and national\u002FEuropean regulations\n\nKey exclusion criteria are:\n\n1. (Oligo)metastatic disease\n2. Histologically or cytologically confirmed diagnosis other than squamous cell carcinoma or adenocarcinoma (eg. neuroendocrine carcinoma, lymphoma…)\n3. Other active malignancies\n4. Previous exposure to chemoradiation (prior to MDT)\n5. Treatment plan after MDT: neoadjuvant chemotherapy with no radiation or chemoradiation with definitive intent (surgery is not planned)",{"count":386,"type":21},248,[83],"Purpose of this study is to determine the value of liquid biopsies, e.g. testing of minimal residual disease (MRD) by using liquid biopsies to measure circulating tumour DNA (ctDNA) at diagnosis and during the multimodal and multidisciplinary curative-intent treatment of resectable esophageal cancer.",[390],"Esophageal Cancer",{"date":241,"type":30},{"date":393,"type":30},"2023-03-29",{"date":395,"type":21},"2029-12-31",{"name":36,"class":37},{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":304,"enrollmentInfo":405,"targetDuration":4,"studyType":50,"phases":406,"briefSummary":407,"conditions":408,"keywords":411,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":419,"leadSponsor":421,"locationsCount":38},"100618338","cares--customized-aftercare-report-for-evaluated-skin-cancer-patients-100618338","NCT07330323","CARES : Customized Aftercare Report for Evaluated Skin Cancer Patients","Development and Evaluation of a Personalized Discharge Letter for Low-risk Skin Cancer Patients After Dermatological Screening.","CARES","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n* Low-risk skin cancer patients:\n\n  1. Negative personal history for melanoma\n  2. Less than 100 naevi\n  3. Less than 5 clinically atypical naevi\n  4. Maximum 1 BCC in history\n  5. Maximum 1 SCC, and at least 5 years ago\n  6. AK: treated and controlled with clinical response\n  7. M Bowen: treated and controlled with clinical response\n* Adult subjects (between 18 years of age and 80 years) at time of enrolment\n\nExclusion Criteria:\n\n* Presence of dermatological lesions requiring immediate treatment at the time of consultation.\n* History of solid organ transplantation (Organ Transplant Recipient, OTR).\n* Known carriers or suspected carriers (based on family history) of germline mutations associated with increased skin cancer risk (e.g. CDKN2A, PTCH1, XP genes).\n* Failure to meet one or more of the inclusion criteria.\n* Any condition or comorbidity that, in the opinion of the investigator, may interfere with study participation or data interpretation (e.g. severe cognitive impairment, language barrier).\n* Participation in another interventional clinical trial that may interfere with the outcomes of this study.",{"count":211,"type":21},[83],"Current clinical practices often provide general verbal advice to low-risk patients, which may not sufficiently address individual concerns or offer actionable steps. Generic information on the internet can be overwhelming or unreliable, leading to confusion and unnecessary follow-up visits.\n\nThis project introduces a tailored approach by combining evidence-based guidelines with personalized details about the patient's risk profile. The discharge letter bridges the gap between clinical expertise and patient understanding, offering clear, specific, and actionable advice that has been shown to improve health behaviors and outcomes in other contexts .\n\nThe personalized discharge letters are generated using an AI agent trained on validated letters from the hospital's electronic health record system (KWS). Each letter is reviewed and approved by a physician before being provided to the patient, ensuring both accuracy and clinical relevance.",[409,410,193],"Management","Low Risk",[412,413,414],"Skin cancer risk and management","personalized discharge letter","low-risk skin cancer patients","2026-05-20",{"date":417,"type":30},"2026-05-22",{"date":415,"type":30},{"date":420,"type":21},"2029-06",{"name":36,"class":37},{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":430,"enrollmentInfo":431,"targetDuration":4,"studyType":50,"phases":433,"briefSummary":434,"conditions":435,"keywords":437,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":443,"leadSponsor":445,"locationsCount":38},"100634177","clinical-decision-making-in-fais-100634177","NCT07536295","Clinical Decision-Making in FAIS","Optimizing Treatment Pathway and Clinical Desicion-making in Young Adults With Femoroacetabular Impingement Syndrome","CDM-FAIS","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n2. Male or Female, Age 18-35 years inclusive.\n3. First consultation at participating site with clinical diagnosis of FAIS by a hip orthopaedic surgeon, including positive impingement tests and reduced hip ROM in the transverse plane compatible with FAIS.\n4. Radiographic cam and\u002For pincer morphology on standard imaging (e.g. α-angle \\>60°, lateral center-edge angle \\>40°, crossover sign) as per local protocol.\n5. Willingness and ability to participate rehabilitation and complete the recommended physiotherapy sessions and attend scheduled follow-up visits.\n6. Ability to perform basic squat \u002F hip-hinge tasks safely in the motion lab, as judged by the treating clinician.\n\nExclusion Criteria:\n\n1. Previous surgery on the bilareral hip.\n2. History of major hip trauma or pediatric hip disease (e.g. Slipped capital femoral epiphysis, Perthes disease).\n3. Developmental dysplasia (lateral center-edge ≤20°) or other severe structural deformity incompatible with the standard FAIS pathway.\n4. Radiographic signs of hip degeneration (Tönnis grade \\>2).\n5. Other musculoskeletal conditions that significantly interfere with assessments (e.g. symptomatic lumbar disc disease, severe knee pathology, recent adductor muscle pathology).\n6. Contraindications to MRI (e.g. non-MRI compatible pacemaker or implant, severe claustrophobia not manageable with standard care).\n7. Contraindications to X-ray or MRI related to pregnancy: known pregnancy at any time, or positive pregnancy test prior to imaging; breastfeeding women will not undergo additional research imaging.\n8. Inability to perform basic squat\u002Fhip-hinge tasks safely (e.g. due to balance, pain or cardiopulmonary limitations).","35 Years",{"count":432,"type":21},60,[83],"Femoroacetabular impingement syndrome is increasingly recognized as a contributor to cartilage injury and early hip osteoarthritis. Both structured conservative care and arthroscopic surgery can improve pain and function, but a major unresolved clinical problem is deciding who should continue conservative care and who should escalate to surgery, and when. Evidence indicates that shorter symptom duration before surgery is associated with better long-term improvement, meaning delays may reduce the chance of achieving meaningful recovery. Current decision-making still depends largely on static imaging and passive clinical examination, which do not capture the dynamic, movement-related nature of the condition, while advanced three-dimensional imaging and laboratory motion analysis are not practical for routine clinical monitoring. This study aims to address this gap by developing and validating feasible, clinic-ready dynamic assessment methods and integrating weight-bearing pelvic and spinal alignment with three-dimensional hip modeling to support more objective, individualized, and timely treatment decisions.",[436],"Femoracetabular Impingement",[438],"FAIS","2026-05-05",{"date":441,"type":30},"2026-05-06",{"date":32,"type":21},{"date":444,"type":21},"2029-07",{"name":36,"class":37},{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":452,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":50,"phases":456,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":465,"locationsCount":38},"100540834","phase-2-nodular-shrinking-in-dupuytren-disease-100540834","NCT06321991","Nodular Shrinking in Dupuytren Disease","Nodular Shrinking in Stage 0 Dupuytren Disease: an Evidence-based Approach for Early Stage Treatment to Prevent Progression to Advanced Finger Contractures","Echo","Inclusion Criteria:\n\n* The participant or his\u002Fher legally authorized representative voluntary signed the informed consent prior to the first assessment.\n* Participants are ≥ 18 years and diagnosed with primary Dupuytren disease.\n* Included patients have a stage 0 DD (nodule of at least 5 mm in the involved hand without contracture).\n* The participant has well distinguished noduli that are clearly visible on US (ultrasound)\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years.\n* Patient included in an interventional trial with an investigational medicinal product.\n* Patients with cognitive impairments, severe rheumatic disease and neurological disorders leading to flexion deformities of the fingers.\n* Patients with prior Dupuytren surgery in the involved hand.\n* Patients with a higher Tubiana grading than nodular stage 0.\n* Open wound in the palm of the treated hand.",{"count":455,"type":21},80,[52],"Dupuytren disease (DD) is a common hand disorder with disabling finger contractures that may require surgery to restore function. In the early stages of the disease, the nodules (Tubiana stage 0) are usually painless, but a reason for concern to many patients. Not rarely, lifestyle measures and even risky treatment options as radiotherapy are advised, yet no therapy to prevent disease evolution has a solid proven effect. Furthermore, reliable non-invasive measurement of early stage DD is not validated.\n\nEvidence was found that pharmacotherapy may influence DD evolution, but valuable clinical trials are limited. Case series and non-published explorative follow-up suggested local treatment with antioxidant vitamin E to possibly interfere with an evolution of DD nodules to contracting strands. This study aims to provide evidence on efficiency of this non-invasive treatment option.\n\nSecure measurement of nodule evolution is a clinical challenge. To measure this evolution, ultrasound and MRI scanning are currently being performed. Stage 0 (nodules) is more challenging to quantify. A strict individual follow-up by the treating clinician is needed to standardize measurement of selected (treated) nodules. Therefore, simple ultrasound by the treating clinician may provide an good tool to collect data. This study aims to introduce and validate this non-invasive scan method and provide a prospective double blind investigation of a measurable effect of non-invasive preventive treatment for stage 0 DD to improve clinical outcome.",[459],"Dupuytren's Disease",{"date":461,"type":30},"2026-05-11",{"date":463,"type":30},"2024-02-15",{"date":294,"type":21},{"name":36,"class":37},{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":4,"enrollmentInfo":474,"targetDuration":4,"studyType":50,"phases":476,"briefSummary":477,"conditions":478,"keywords":480,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":483,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":487,"locationsCount":38},"100510235","changing-tactics-optimizing-ect-in-difficult-to-treat-depression-100510235","NCT05923801","Changing Tactics? Optimizing ECT in Difficult-to-treat Depression","Changing Tactics? Optimizing ECT in Difficult-to-treat Depression: A Randomized Trial Comparing Continuation of Right Unilateral ECT and Switching to Bitemporal ECT in Case of Early Non-response During an Acute Course of ECT for Difficult-to-treat Depression","ChaT","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n* Age 18 or older\n* Diagnosis of major depressive disorder (DSM-5 296.21-30) or bipolar disorder, depressed (DSM-5 296.51-54; 296.84).\n\nExclusion Criteria:\n\n* Contra-indication for general anesthesia\n* Non-Dutch speaking\n* Diagnosis of schizoaffective disorder or schizophrenia\n* Diagnosis of substance use disorder in the past six months\n* Diagnosis of neurocognitive disorder or intellectual disability alongside a MoCA score \\\u003C23\n* Previous ECT course in the past three months\n* Participation in an interventional Trial with an investigational medicinal product or device\n* Pregnancy",{"count":475,"type":21},196,[83],"The goal of this randomized controlled trial is to address which treatment strategy (continue right unilateral (RUL) ECT or switch to bitemporal (BT) ECT speeds up recovery and has the least impact on memory function, in case of early non-response during an acute course of ECT for difficult-to-treat depression.\n\nThe main questions it aims to answer are:\n\n* Assess the antidepressant efficacy and cognitive impact of the continuation of an ongoing treatment with RUL ECT compared to switching the treatment technique to BT ECT, in patients failing to show an early response to an acute course of ECT for major depression;\n* Assess group and subject-specific trajectories of depressive symptom severity and neurocognitive performance during the acute ECT course and up to 3 months post-treatment.\n\nParticipants treated with ECT for depression, showing no 'response' (≥50 percent decrease in depressive symptom severity compared to baseline) after 4 treatment sessions, will be randomized to either switch to BT ECT or continue with RUL ECT. Mood and neurocognitive assessments will be performed at baseline, after 4 ECT sessions (before randomization), after 8 ECT sessions, at the end of the acute course and 3 month after the acute course.",[479],"Depression",[481,479,482],"Electroconvulsive Therapy","Cognition",{"date":461,"type":30},{"date":485,"type":30},"2023-06-01",{"date":241,"type":21},{"name":36,"class":37},{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":129,"sex":18,"minAge":496,"maxAge":497,"enrollmentInfo":498,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":500,"conditions":501,"keywords":503,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":512,"startDateStruct":513,"completionDateStruct":515,"leadSponsor":517,"locationsCount":38},"100561030","3d-microscopic-muscle-architecture-in-cerebral-palsy-100561030","NCT06584851","3D-Microscopic Muscle Architecture in Cerebral Palsy","Evaluation of Microscopic Muscle Properties in Growing Children With Cerebral Palsy and Their Relation to Macroscopic Muscle Properties","3D-MMAP","CHILDREN WITH CP\n\nInclusion criteria\n\n* Children (boys\u002Fgirls) diagnosed with predominantly spastic type of CP\n* Uni- or bilateral involvement\n* Gross Motor Function Classification Scale (GMFCS) Level I-III50\n* 2 to 9 years of age\n* Planned for an orthopedic intervention that requires general anesthesia (botulinum toxin injections, orthopedic surgery, or diagnostic imaging such as Magnetic Resonance Imaging \\[MRI\\], etc.)\n\nExclusion criteria\n\n* Presence of dystonia or ataxia\n* Previous surgery less than 6 months at the investigated muscles\n* Severe co-morbidities (that are likely to prevent proper assessment, such as severe cognitive problems)\n\nTYPICALY DEVELOPING CHILDREN\n\nInclusion criteria\n\n* Children (boys\u002Fgirls)\n* 2 to 9 years of age\n* Planned for a surgical intervention that requires general anesthesia (pure pediatric upper limb orthopedic surgery or trauma surgery, or ophthalmic or ear-nose-throat surgery)\n\nExclusion criteria\n\n* History of neurological problems\n* History of orthopedic problems at the gastrocnemius or semitendinosus\n* Trauma at the level of the lower limbs\n* Involvement in an elite or high-performance sporting program (Children performing sports for \\> 3 5 hours\u002Fweek will be excluded)\n\nADOSESCENTS WITH HSP of 12-18 years old and ADULTS WITH HPS\n\nInclusion criteria\n\n* Adolescents (boys\u002Fgirls) or adults (male\u002Ffemale) diagnosed with HSP, SPG3a or SPG4\n* Gross Motor Function Classification Scale (GMFCS) Level I-III50\n* Adolescents 12 to 18 years or adults 18-40 years of age\n\nExclusion criteria\n\n* Presence of dystonia or ataxia\n* Previous surgery less than 6 months at the investigated muscles\n* Severe co-morbidities (that are likely to prevent proper assessment, such as severe cognitive problems)\n\nTYPICALLY DEVELOPING ADOLESCENTS of 12-18 years old and HEALTHY ADULTS (age- and gender-matched with the recruited HSP patients)\n\nInclusion criteria\n\n* Typically developing adolescents (boys\u002Fgirls) and healthy adults (male\u002Ffemale), who are age and gender matched with the recruited HSP participants\n* Adolescents 12-18 years of age or adults 18-40 years of age\n\nExclusion criteria\n\n* History of neurological problems\n* History of orthopedic or muscular problems at the gastrocnemius\n* Trauma at the level of the lower limbs\n* Involvement in an elite or high-performance sporting program (participants performing sports for \\> 5 hours\u002Fweek will be excluded)\n* Sport session less than 72 hours prior to the biopsy collection","2 Years","9 Years",{"count":499,"type":21},130,"The focus of this study is to understand and define the mechanisms of the altered muscle development and growth on a microscopic level within a long-term perspective in children with cerebral palsy and to relate these findings to muscle macroscopic properties defined by muscle imaging, to neuromuscular symptoms and to treatment.\n\nThis study aims to (1) evaluate intrinsic microscopic muscle properties of young growing children with CP, and (2) to evaluate these muscle properties in relation to macroscopic properties, neuromuscular symptoms and to treatment.\n\nImproved understanding of changes in microscopic muscle properties, and how they relate to macroscopic properties and to the neuromuscular symptoms as well as how they are influenced by treatment, has the potential to delineate CP phenotypes prone to intervention and to optimize treatment protocols or develop new treatments, leading to new avenues for improving function in CP.\n\nThe method to study microscopic muscle properties involves analysis of muscle biopsies (histological \u002F immunohistochemistry analysis, SC and IC culture, gene expression). Biopsies will be collected using the minimally invasive percutaneous needle microbiopsy technique, suitable for collecting repeated samples over time in the same individual while still leading to sufficient tissue of good quality for subsequent analysis1,2. For the children with CP, the local hospital's tradition of applying general anesthesia for delivering BTX injections will be exploited to collect the muscle samples prior to the BTX session and the one-year follow-up, or general anesthesia planned for orthopedic surgery or diagnostic imaging such as MRI, etc. For the collection of the samples 3 months before the BTX session, as well as 3 months and 6 months after BTX injections, the common approach for microbiospy collection will be applied, with local sedation on the skin (Rapydan©) and fascia (Xylocaine©) and local anesthesia by using Kalinox© (nitrous oxide in oxygen) under supervision of the University Hospital PROSA team. Biopsies of TD muscles will be collected in children with no history of neurological disorder, nor musculoskeletal problems at the level of the gastrocnemius or semitendinosus, at the time of upper limb orthopedic or trauma surgery and thus always under general anesthesia. Ultrasound guided percutaneous muscle biopsy has been performed in children (2 months-18 years)3,4 and has proven to be safe and well-tolerated. A pilot study (S61110) was conducted to confirm that the microbiopsy technique is suitable for the analysis of microscopic muscle properties and is well-tolerated in children with CP.\n\nTwo specific research goals are planned, with hypotheses emerging from literature.",[502],"Spastic Cerebral Palsy",[504,505,506,507,508,509,510],"Spastic cerebral palsy","Microscopic muscle properties","Muscle micro-biopsies","3D freehand ultrasound","Histology","Cell culture","CP-phenotypes","2026-05-04",{"date":439,"type":30},{"date":514,"type":30},"2019-05-02",{"date":516,"type":21},"2028-12",{"name":36,"class":37},{"id":519,"slug":520,"hasResults":12,"nctId":521,"briefTitle":522,"officialTitle":522,"acronym":523,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":18,"minAge":233,"maxAge":47,"enrollmentInfo":525,"targetDuration":4,"studyType":50,"phases":527,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":539},"100545343","stepwise-heat-denaturated-protein-introduction-for-tolerance-induction-in-food-allergy-100545343","NCT06380673","Stepwise Heat-Denaturated Protein Introduction for Tolerance Induction in Food Allergy","TEHITI","Inclusion Criteria:\n\n* Children (1-18y) had or have a clinical diagnosis of IgE mediated cow's milk allergy based on positive history as well as skin prick testing and\u002For specific IgE detection by CAPtest in an allergy clinic.\n* Children are at least 12 months old before introduction of heated cow's milk is considered.\n* Children did not suffer from grade 4 anaphylaxis due to cow's milk-ingestion at presentation.\n* Children have specific IgE levels to Bos d 8 below 1.2 kU\u002FmL and\u002For children passed 20' cooked cow's milk provocation test executed on clinical judgement.\n\nExclusion Criteria:\n\n* Children had grade 4 anaphylaxis due to cow's milk ingestion.\n* Children are younger than 12 months old at the moment of passing 20' cooked cow's milk OFC.\n* Parents are not able or not willing to adhere to a specific cow's milk protein-containing diet on a regular basis at home.\n* Multiple food allergy, not compatible with any of the choices in the Flemish Milk Ladder.\n* Parents and\u002For children are not willing to give IC\u002Fassent.",{"count":526,"type":21},90,[83],"This interventional study aims to validate an early heated protein introduction protocol in cow's milk allergic children who already developed tolerance towards extensively heated cow's milk, in order to speed up the development of complete cow's milk tolerance. Natural complete tolerance induction towards cow's milk takes several years of strict cow's milk avoidance with high risk of anaphylaxis by accidental cow's milk intake. By shortening the time towards complete tolerance, not only the quality of life of both children and parents ameliorates drastically, the time frame for potential anaphylactic reactions is also strongly reduced and can be considered as a preventive strategy to reduce allergic reactions too. Moreover, this strategy has proved efficient for hen's egg allergy. The main question this study wants to answer is whether a 12 months stepwise heated cow's milk introduction (either by gradual reduction of the cooking time or by the use of the Flemish Milk Ladder) in 20'-cooked cow's milk tolerant subjects, results in a larger proportion of complete cow's milk tolerant children after 12 months compared to natural tolerance induction (with 20' cooked milk introduction only).",[530,531],"Food Allergy","Cow Milk Allergy",{"date":533,"type":30},"2026-05-08",{"date":535,"type":30},"2024-04-22",{"date":537,"type":21},"2029-12-30",{"name":36,"class":37},5,{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":4,"eligibilityCriteria":545,"healthyVolunteers":12,"sex":18,"minAge":546,"maxAge":47,"enrollmentInfo":547,"targetDuration":4,"studyType":50,"phases":549,"briefSummary":550,"conditions":551,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":553,"startDateStruct":554,"completionDateStruct":556,"leadSponsor":558,"locationsCount":38},"100545385","pediatric-eosinophilic-esophagitis-pedeoe-effect-of-allergen-heat-denaturation-on-eoe-remission-a-pilot-trial-100545385","NCT06381219","Pediatric Eosinophilic Esophagitis (pedEoE): Effect of Allergen Heat Denaturation on EoE Remission: a Pilot Trial","Inclusion Criteria:\n\nAll children (aged 12 months and older) presenting (since 1-1-2014: moment of diagnostic guideline standardization for pedEoE) with diagnosed pedEoE at UZ Leuven eliminating either hen's egg or cow's milk or both and in complete remission after their latest biopsy (no longer than 12 months earlier, but preferentially as short as possible after their latest biopsy) are eligible for the study. If the last biopsy has been performed more than 12 months earlier, a new gastro-duodenoscopy will be performed to verify remission and rule out e.g. active gastritis. If they are on PPI and\u002For local budesonide treatment, this should be stable for at least 3 months and will remain untouched during the entire study. We will include 18 pedEoE subjects suffering from cow's milk induced EoE and 18 suffering from hen's egg induced EoE.\n\nExclusion Criteria:\n\n* Children younger than 12 months\n* Children with active pedEoE\n* Children who refuse to adhere to the protocol\n* Children with associated IgE mediated hen's egg and\u002For cow's milk allergy with specific IgE antibody titers that predict active (baked egg and\u002For baked milk) food allergy with cut-off titers as used at the consultation of allergy (KLL). Those children will become eligible however if their titers decrease while the study is still open.","12 Months",{"count":548,"type":21},36,[83],"The objective of the study is to study whether the introduction of heated food products (more specifically heated hen's egg and\u002For cow's milk) in children with EoE would be possible without re-occurrence of the eosinophilic inflammation, while the intake of less heated products might cause disease recidive. Moreover, we would like to study whether the gradual re-introduction of less heated products after the most heated form is tolerated, could lead to tolerance induction in EoE.",[552],"Eosinophilic Esophagitis",{"date":439,"type":30},{"date":555,"type":30},"2023-12-19",{"date":557,"type":21},"2028-12-31",{"name":36,"class":37},{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":18,"minAge":567,"maxAge":568,"enrollmentInfo":569,"targetDuration":4,"studyType":50,"phases":570,"briefSummary":571,"conditions":572,"keywords":573,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":511,"lastUpdatePostDateStruct":578,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":38},"100519486","feasibility-nutritional-supplements-for-muscle-growth-in-cp-100519486","NCT06044168","Feasibility Nutritional Supplements for Muscle Growth in CP","Feasibility Study: Nutritional Supplements to Support Muscle Growth in Children With Cerebral Palsy","Nut-CP","Inclusion Criteria:\n\nSpastic Cerebral Palsy (diagnosed by a neuro-pediatrician from the CP Reference Centre of the University Hospital Leuven)\n\n* Uni- of bilateral involvement\n* Level II or III on the Gross Motor Function Classification System (GMFCS)\n* Muscle volume for the medial gastrocnemius (target muscle) of at least 20% compared to the expected muscle volume in age-matched typically developing children\n\nExclusion Criteria:\n\n* Presence of dyskinesia or ataxia\n* Severe co-morbidities\n* Botulinum toxin treatment ten months prior to assessment\n* Previous orthopedic or neurosurgery\n* Severe ankle deformities preventing fitting in test positions\n* Ankle range of motion (ROM) \\\u003C30% of normal values","4 Years","10 Years",{"count":539,"type":21},[83],"The purpose of this study is to investigate the feasibility of a 10-week plan with a nutritional supplement (leucine) and to perform pilot analyses on the effect of leucine on macroscopic muscle morphology in children with cerebral palsy.",[502],[502,507,574,575,576,577],"Muscle morphology","Nutritional supplements","Leucine","Feasibility",{"date":439,"type":30},{"date":580,"type":30},"2023-07-31",{"date":582,"type":21},"2027-12",{"name":36,"class":37},{"id":585,"slug":586,"hasResults":12,"nctId":587,"briefTitle":588,"officialTitle":589,"acronym":590,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":592,"enrollmentInfo":593,"targetDuration":4,"studyType":50,"phases":594,"briefSummary":595,"conditions":596,"keywords":599,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":611},"100553134","dysfunction-of-olfaction-after-covid-19-infection-morphological-and-histomolecular-investigation-100553134","NCT06482138","Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation","Dysfunction of Olfaction After SARS-CoV-2 Infection: Morphological and Histomolecular Investigation of Olfactory Cleft Biopsies and Cytobrushes","DysOSMIC","Inclusion Criteria:\n\n* Olfactory Dysfunction group: Presence of evident OD (Parosmia, Threshold-Discrimination-Identification (TDI)-score ≤24, Subjective abnormal quantitative olfactory function; measured by a visual analogue score (VAS) of smell impairment ≥5\u002F10\n* Control group: No OD (TDI-score \\>30.5.)\n\nExclusion Criteria:\n\n* Presence of concomitant nasal mucosal pathology that might affect olfactory function or bias the study investigations\n* Use of anticoagulation therapy\n* Allergy to local anesthetics","70 Years",{"count":133,"type":21},[83],"Investigation of the mechanisms of persistent SARS-CoV-2 associated olfactory dysfunction (OD) in patients with well-documented olfactory function. The investigators plan to collect olfactory cleft biopsies and cytobrushes in COVID-19 patients and controls.",[597,598],"Covid19","Olfactory Dysfunction",[598,600,601,602,603],"COVID-19","SARS-CoV-2","Anosmia","Hyposmia","2026-04-30",{"date":441,"type":30},{"date":607,"type":30},"2024-01-24",{"date":609,"type":21},"2026-12-31",{"name":36,"class":37},7,{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":617,"acronym":4,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":18,"minAge":47,"maxAge":619,"enrollmentInfo":620,"targetDuration":621,"studyType":22,"phases":4,"briefSummary":622,"conditions":623,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":627,"startDateStruct":628,"completionDateStruct":630,"leadSponsor":631,"locationsCount":296},"100404318","the-role-of-the-nasal-allergen-provocation-test-in-starting-and-monitoring-allergen-immunotherapy-100404318","NCT04544774","The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy","The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy: An Academic Multicentre Clinical Study","Inclusion Criteria:\n\n* Age \\>18 and ≤60 years\n* Persistent or intermittent allergic rhinitis complaints, confirmed by SPT and\u002Fof immunocap for the specific IgEs.\n\nOR suspected local allergic rhinitis\n\n* Patients who start with AIT treatment\n* The patient must be motivated and willing to come to all visits\n* The patient must be able to understand and sign the informed consent\n\nExclusion Criteria:\n\n* Uncontrolled asthma\n* Conditions affecting the functioning of the immune system (eg: immune deficiencies, malignancies, autoimmune diseases)\n* Use of β-blockers, immunosuppressants or ACE inhibitors\n* Hypersensitivity to aluminum hydroxide and\u002For hypersensitivity to any of the excipients in AIT\n* Anaphylaxis after allergen challenge in the past\n* Acute rhinosinusitis in the last 12 weeks\n* Recent surgery on the nose and\u002For paranasal sinuses in the last 12 weeks\n* Pregnancy","60 Years",{"count":20,"type":21},"3 Years","This prospective multicentric academic NAPT study aims to compile a database of all patients who initiate immunotherapy.\n\nThe NAPT will take place before, during and after AIT to evaluate the cost and effectiveness of the treatment. The study consists of 4 visits and 2 telephone contacts that are repeated annually for 3 years.\n\nThis study will be conducted in 2 hospitals: UZ Leuven and AZ ST. Jan Brugge on the consultation Ear, Nose and Throat Diseases (ENT) and the department of Internal Medicine \u002F Allergology",[624,625,626],"Perennial Allergic Rhinitis","Seasonal Allergic Rhinitis","Local Allergic Rhinitis",{"date":220,"type":30},{"date":629,"type":30},"2020-07-16",{"date":322,"type":21},{"name":36,"class":37},""]